Iterum Therapeutics plc (ITRMF)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$11.0M
Cash & Equivalents
$15.3M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$3M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-10-01 Phase1 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07092813 Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents PHASE1 Recruiting 12

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ITRMF.

SEC EDGAR Filings

All SEC filings for Iterum Therapeutics plc on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.